EU CHMP Finalizes Outstanding Issues On Aimovig And Symproic

 
• By Maureen Kenny
  
Generate a summary of this article
Listen to this article
Beta

EU regulators meeting in London are finalizing the outstanding questions they have for companies whose products are approaching the final stages of the approval process.

boexes marked with green check marks
A number of products are nearing the final stage of the EMA review process

The sponsors of 11 products at the later stages of evaluation at the European Medicines Agency are finding out this week what remaining concerns the agency has with their marketing authorization applications (MAAs). The products include Aimovig (erenumab), a potential new migraine treatment from Amgen/Novartis, Shionogi/Purdue Pharma’s Symproic (naldemedine) for opioid-induced constipation (OIC) in adults, and Dsuvia (sufentanil) from AcelRx Pharmaceuticals for the management of acute moderate to severe pain.

The 11 products also include three biosimilar versions of AbbVie Inc.'s Humira (adalimumab) and one biosimilar of Johnson...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Europe

EU Biosimilar Filings, Opinions And Approvals

 
• By Saba Afreen

<p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>

EU Pharma Reform: What You Need to Know Now

 
• By Anabel Costa-Ferreira and Ian Schofield

As the reform of the EU pharmaceutical legislation progresses through the legislative process, the Pinks Sheet offers an infographic highlighting some of the key changes being proposed that will reshape the way drug companies run their business.

New EU Approvals

<p>Executive Summary<p> <p>The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add six new products, incl/ding Ixchiq, Valneva's chikungunya virus vaccine</p>

More from Geography

Canada Cuts Red Tape With Single Ethics Review For Trials

A new research ethics review system for multi-site clinical trials in Canada is expected to help improve study start-up times, avoid unnecessary duplication and boost the country’s competitiveness on a global stage.

Nancy Test Circulable Section Geography

 
• By Brian Bossetta

This is a short description

Diversity Action Plans: What To Submit And When

 
• By Nielsen Hobbs

With the deadline for comments on the US FDA’s draft guidance less than a month away, the Pink Sheet offers an infographic outlining what the agency is expecting in diversity action plans and when that might be implemented.